A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects (NCT00301483) | Clinical Trial Compass
UnknownPhase 2
A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects
South Africa53 participantsStarted 2004-07
Plain-language summary
The main purpose of this study is to determine if HBOC-201 is safe and tolerable to trauma subjects, when given to treat the inadequate supply of blood and nutrients to tissues and organs.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
INCLUSION CRITERIA:
* Male or Female (females not of childbearing potential or negative pregnancy test prior to enrollment)
* Age ≥ 18 years and ≤ 65 years of age
* Trauma with bleeding or a potential for bleeding arriving at initial treatment facility directly from scene of injury
* Subject should be enrolled within four (4) hours of injury
* Base Deficit (BD) greater than 5.0 and one of the following:
Systolic Blood Pressure ≤ 100 mm Hg OR Sustained (≥ 10 minutes) Heart Rate ≥ 100
* No localized signs of traumatic brain injury and a Glasgow Coma Score of ≥9 with the exception of drug-induced lowered GCS.
* Informed consent, or independent physician authorization obtained
EXCLUSION CRITERIA:
* Known or suspected Traumatic Brain Injury
* Non-survivable injury (Falcone Criteria)
* Traumatic arrest
* Known prior cardiac arrest (i.e., preceding trauma episode)
* Known or suspected pregnancy
* Known allergy to bovine products
* Prior treatment with blood (subsequent to current trauma)
* Informed consent or independent physician authorization unable to be obtained
* Unable to meet protocol or follow-up criteria
What they're measuring
1
Safety/Tolerability of HBOC-201 for treatment of hypoperfusion in trauma by analysis of AEs/SAEs attributed to study drug
Timeframe: Duration of the study (Randomization through 28-day follow-up)